Strategic funding Dorsata has completed a $5.2M Series A in 2020 and has a total funding of $16M, indicating access to capital for product development and go-to-market initiatives. This suggests readiness for expansion efforts, larger pilot programs, or enterprise sales cycles with health plans and provider groups.

Ob-Gyn focused EHR The product is co-designed with hundreds of Ob-Gyns and embedded in obstetrics workflows, offering a strong competitive position in women’s health. This opens opportunities to upsell to life sciences and health plans seeking richer clinical data and seamless workflow integration.

Partnership momentum Recent collaboration activity includes a custom care module development with a 250+ physician OB-GYN group and a stated partnership with Aspira Women’s Health. This signals receptiveness to co-development deals and potential for expanding to larger networks or referrals.

Legal and competitive dynamics Dorsata has engaged in lawsuits against Athenahealth and Unified Women’s Healthcare, which may impact competitive positioning and channel strategy. This suggests a need for careful messaging, risk assessment, and potential emphasis on differentiation and compliance in sales pitches.

Market fit and growth potential With a mid-sized team (11-50 employees) and revenue in the lower to mid range, Dorsata sits in a growth-ready niche: enterprise healthcare IT for obstetrics. Prospects include expanding to broader payer networks, hospital systems, and specialty clinics seeking EHR-embedded data capture and analytics capabilities.